Showing results (31-40 of 41) with videos related to

Sort By:
Pageof 5
Oncotarget|May 13, 2015
CIP2A is a candidate therapeutic target in clinically challenging prostate cancer cell populationsAnchit Khanna, Jayant K Rane, Kati K Kivinummi, et al.
Nature Communications|November 19, 2025
Spatial multi-omics identifies aggressive prostate cancer signatures highlighting pro-inflammatory chemokine activity in the tumor microenvironmentSebastian Krossa, Maria K Andersen, Elise M Sandholm, et al.
Oncotarget|April 19, 2017
Lipid degradation promotes prostate cancer cell survivalHarri M Itkonen, Michael Brown, Alfonso Urbanucci, et al.
Medrxiv : the Preprint Server for Health Sciences|March 3, 2023
Enhancer profiling identifies epigenetic markers of endocrine resistance and reveals therapeutic options for metastatic castration-resistant prostate cancer patientsTesa M Severson, Yanyun Zhu, Stefan Prekovic, et al.
Cell Reports. Medicine|July 3, 2025
Epigenetic profiling identifies markers of endocrine resistance and therapeutic options for metastatic castration-resistant prostate cancerTesa M Severson, Emma Minnee, Yanyun Zhu, et al.
Cell Reports|June 8, 2017
Androgen Receptor Deregulation Drives Bromodomain-Mediated Chromatin Alterations in Prostate CancerAlfonso Urbanucci, Stefan J Barfeld, Ville Kytölä, et al.
Nature Biotechnology|June 13, 2022
Estimation of tumor cell total mRNA expression in 15 cancer types predicts disease progressionShaolong Cao, Jennifer R Wang, Shuangxi Ji, et al.
Nature Communications|November 16, 2024
Single cell and spatial transcriptomics highlight the interaction of club-like cells with immunosuppressive myeloid cells in prostate cancerAntti Kiviaho, Sini K Eerola, Heini M L Kallio, et al.
Cell|August 27, 2025
Tumor transcriptome-wide expression classifiers predict treatment sensitivity in advanced prostate cancersEmily Grist, Peter Dutey-Magni, Marina A Parry, et al.
Research Square|February 17, 2023
Clinical testing of transcriptome-wide expression profiles in high-risk localized and metastatic prostate cancer starting androgen deprivation therapy: an ancillary study of the STAMPEDE abiraterone Phase 3 trialMarina A Parry, Emily Grist, Larissa Mendes, et al.
Pageof 5